Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019: A Case Report

Ryota Hase; Rika Kurata; Keiko Ishida; Takashi Kurita; Emiri Muranaka; Haruki Mito

doi:10.2169/internalmedicine.5377-20

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019: A Case Report

Ryota Hase, Rika Kurata, Keiko Ishida, Takashi Kurita, Emiri Muranaka, Haruki Mito

著者情報

キーワード: acute gouty arthritis, coronavirus disease 2019, favipiravir, hyperuricemia, severe acute respiratory syndrome coronavirus 2

ジャーナルオープンアクセス早期公開

論文ID: 5377-20

DOI https://doi.org/10.2169/internalmedicine.5377-20

この記事には本公開記事があります。

The final version of this article is now available: Vol. 59 (2020), No. 18 pp. 2327-2329

詳細

抄録

A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）